Page last updated: 2024-11-13

lhrh, n-acetyl-(4-chlorophenylalanyl)(1)-(4-chlorophenylalanyl)(2)-tryptophyl(3)-arginyl(6)-alanine(10)-

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

LHRH, N-acetyl-(4-chlorophenylalanyl)(1)-(4-chlorophenylalanyl)(2)-tryptophyl(3)-arginyl(6)-alanine(10)-: gonadorelin antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID25074888
MeSH IDM0524308

Synonyms (18)

Synonym
organon 30276
lhrh, n-acetyl-(4-chlorophenylalanyl)(1)-(4-chlorophenylalanyl)(2)-tryptophyl(3)-arginyl(6)-alanine(10)-
gnrhant
org-30276
aptaa-lhrh
d-alanine, n-(1-(n2-(n-(n2-(n-(n-(n-(n-(n-acetyl-4-chloro-d-phenylalanyl)-4-chloro-d-phenylalanyl)-d-tryptophyl)-l-seryl)-l-tyrosyl)-d-arginyl)-l-leucyl)-l-arginyl)-l-prolyl)-
n-ac(1)-(4-cl-phe)-2-(4-cl-phe)-3-trp-6-arg-10-ala-lhrh
ac-d-pclphe-d-pclphe-d-trp-ser-tyr-d-arg-leu-arg-pro-d-ala-nh2-ch3-cooh
d-alanine, n-acetyl-4-chloro-d-phenylalanyl-4-chloro-d-phenylalanyl-d-tryptophyl-l-seryl-l-tyrosyl-d-arginyl-l-leucyl-l-arginyl-l-prolyl-
org-31276
d-alanine, n-(1-(n(sup 2)-(n-(n(sup 2)-(n-(n-(n-(n-(n-acetyl-4-chloro-d-phenylalanyl)-4-chloro-d-phenylalanyl)-d-tryptophyl)-l-seryl)-l-tyrosyl)-d-arginyl)-l-leucyl)-l-arginyl)-l-prolyl)-
org 30276
83539-08-6
unii-d0nof0et2c
gnrh, n-ac-(4-cl-phe)(1)-(4-cl-phe)(2)-trp(3)-arg(6)-ala(10)-
d0nof0et2c ,
DTXSID10232431
AKOS040746585

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"A GnRH antagonist, Ac-D-p-Cl-Phe1,2, D-Trp3, D-Arg6, D-Ala10 GnRHb (Organon), was utilized to determine the effective dosage and duration to inhibit LH secretion in the pig."( GnRH antagonist inhibition of luteinizing hormone secretion and ovulation in the pig.
Geisert, RD; Hill, CM; McCann, JP; Minton, JE; Morgan, GL; Patterson-Bay, DJ, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (32.69)18.7374
1990's28 (53.85)18.2507
2000's5 (9.62)29.6817
2010's1 (1.92)24.3611
2020's1 (1.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.60 (24.57)
Research Supply Index4.04 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.82%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other54 (98.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function [NCT03112226]19 participants (Actual)Interventional2018-02-07Completed
Extended High Dose Letrozole Regimen Versus Short Low Dose Letrozole Regimen as an Adjuvant to GnRH Antagonist Protocol in the Management of Patients With Poor Ovarian Response Undergoing IVF-ET, a Randomized Controlled Trial [NCT01219153]Phase 2136 participants (Actual)Interventional2008-09-30Completed
Extended Letrozole Regimen Co-treatment With Gonadotropin Releasing Hormone Antagonist Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in Poor Responders Undergoing IVF-ET. A Randomized Controlled Trial [NCT04268927]Phase 2106 participants (Anticipated)Interventional2018-04-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]